Clinical trial specialist Panthera Biopartners has appointed corporate financier Christopher Steed as a non-executive director to continue its expansion both in the UK and overseas

Independent clinical trial site management organisation (SMO), Panthera Biopartners, has appointed M&A and fundraisings adviser Chris Steed as a non-executive director. Chris has over 25 years’ experience as a corporate financier, working at Arthur Andersen, Deloitte and for the past 17 years as Founder and Managing Partner of Argyll Partners.

Chris has acted as lead advisor on over 125 transactions involving mergers and acquisitions and fundraisings on deals ranging from £4m to £300m. He works as a senior advisor, providing advice to shareholders and the boards of companies covering strategy and shareholder value creation.

Panthera’s Chairman Professor John Lyon commented: “We are delighted that Chris has joined us as a non-executive director. His great experience will be invaluable to us as we continue to grow and build on the rapid expansion of the company. Since our launch in 2019, despite Covid, we will by the end of this year have extended our UK network to ten sites. We are now looking at overseas opportunities and intend with Chris’s help to become a significant global player.”

Panthera is currently involved in running clinical trials on behalf of its clients in pharma and CROs including several COVID 19 studies as well as trials in oncology, NASH, neurology, and conditions treated in primary care.